Contents
Metocard ZK is a beta-blocker drug that reduces the heart rate and the strength of its contraction, and lowers blood pressure. The preparation is indicated for the treatment of angina and the prevention of recurrent infarction and migraine attacks. The active substance is metoprolol. Metocard ZK is in the form of prolonged-release tablets and is available on prescription.
Metocard ZK, Producer: Polpharma
| form, dose, packaging | availability category | the active substance |
| extended release tablets; 23,75 mg, 47,5 mg, 95 mg; 28 pieces | prescription drug | metoprolol |
Metocard ZK – indications for use
Metocard ZK is a preparation indicated in the treatment of:
- arterial hypertension,
- angina,
- heart rhythm disturbances,
- supraventricular tachycardia,
- palpitations (caused by heart problems)
- stable symptomatic heart failure (NYHA class II-IV, left ventricular ejection fraction less than 40%) in combination with other drugs used in the treatment of heart failure.
Metocard ZK prevents:
- death from cardiac causes,
- another heart attack,
- migraine.
Metocard ZK – contraindications to taking
Contraindications to the use of Metocard ZK are:
- hypersensitivity to any component of the preparation or to other drugs from the beta-blocker group, second or third degree atrioventricular block,
- untreated heart failure (pulmonary edema, impaired blood flow or hypotension),
- continuous or periodic use of preparations increasing the strength of contraction of the heart muscle,
- cardiogenic shock,
- sick sinus syndrome,
- symptomatic bradycardia (heart rate less than 50 beats per minute),
- severe circulatory disorders in peripheral arteries,
- arterial hypotension (systolic blood pressure below 90 mm Hg),
- severe bronchial asthma or COPD,
- metabolic acidosis,
- untreated phaeochromocytoma,
- suspicion of a heart attack,
- heart failure and the presence of systolic blood pressure below 100 mm Hg (testing before starting treatment is recommended),
- Parallel use of: monoamine oxidase inhibitors (MAO), intravenous calcium channel blockers, verapamil or diltiazem, or other antiarrhythmic drugs (such as disopyramide).
- use in pregnancy (only with the consent of the doctor, if necessary),
- use during breastfeeding.
Metocard ZK – drug dosage
Metocard ZK is in the form of prolonged-release tablets and should be taken orally. Tablets should be taken whole with a drink of water (do not chew), do not exceed the recommended daily dose of the drug as it may endanger your life or health.
Adults:
- Arterial hypertension: in mild or moderate arterial hypertension 47,5 mg once a day; if necessary, your doctor will increase the dose to 1-95 mg a day or add another antihypertensive drug.
- Angina pectoris: 95-190 mg once daily. If necessary, your doctor may add other medications to treat coronary heart disease.
- Cardiac arrhythmias: 95-190 mg once daily.
- Prevention of death from cardiac causes and recurrence of myocardial infarction after an acute phase of myocardial infarction: 190 mg once a day.
- Palpitations caused by functional heart disorders: 95 mg once a day; your doctor may increase the dose to 1 mg daily if necessary.
- Prevention of migraine attacks: 95-190 mg once daily.
- the dose is determined individually; l
- Initially, in patients with heart failure, NYHA class III-IV, it is 11,88 mg once daily in the first week of treatment; in week 1, the dose may be increased to 1 mg once a day.
- In patients with heart failure, NYHA class II, initially 23,75 mg once daily during the first 1 weeks of treatment; after 2 weeks it is recommended to double the dose. The dose is increased every 2 weeks to 2 mg once a day or to the highest dose tolerated by the patient. In long-term treatment, the target dose is 190 mg once a day (or it is the highest dose tolerated by the patient).
Patients with impaired renal function: no dose adjustment is necessary.
Patients with severe hepatic insufficiency (e.g. portal vein inferior vena cava fusion): the doctor decides to reduce the dose.
Patients over 80 years of age: caution should be exercised when increasing the dose of the drug.
Children and adolescents: there is no specific information on the safety and effectiveness of the medicine.